Page 4 - D Dimer News Today

A recent systematic review and meta-analysis evaluated the safety and efficacy of intensified anticoagulation therapy in COVID-19 patients.

Researchers conduct a multi-center study involving hospitalized COVID-19 patients to gather information on the rationale use of convalescent plasma.

This unique paper compares neurosurgical patients with COVID-19 for perioperative complications to those without COVID-19.

Patients with COVID-19 in the intensive care unit (ICU) prescribed full-dose blood thinners are significantly more likely to experience heavy bleeding than patients prescribed a smaller yet equally effective dose, according to a recent University at Buffalo-led study.

A new preprint reports a novel machine learning model that purportedly predicts the mortality risk of COVID-19 in patients accurately and at an early stage of infection.

Researchers demonstrate that the exposure of platelets to the SARS-CoV-2 spike protein promotes their activation and adhesion.

A team of US-based scientists has recently explored various risk factors associated with the poor prognosis of coronavirus disease 2019 (COVID-19). They have identified thrombosis-related risk factors as a major predictor of in-hospital COVID-19 related mortality. The study is currently available on the medRxiv* preprint server while awaiting peer review.

A screening blood test originally validated in seriously ill patients without COVID-19 is still clinically useful for ruling out pulmonary embolism in patients hospitalized with the coronavirus, a University of South Florida Health (USF Health) Morsani College of Medicine research team reports.

A recent study analyzes real-world data using artificial intelligence to provide insights into using ondansetron, an antiemetic agent, among SARS-CoV-2 positive patients.

In a recent open-access paper published in the Journal of Clinical Medicine, researchers from Iran and Germany show that high baseline levels of inflammatory cytokines measured during admission put patients with coronavirus disease (COVID-19) at increased risk of developing coagulopathy, thrombotic events – and even death.